Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs

Summary

GBI Research’s new report, “Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the diabetes therapeutics market from 2001 to 2009, forecast forward to 2016.
- Market characterization of the diabetes therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development. .
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global diabetes therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table Of Contents

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Global Diabetes Market: Introduction 10
2.1 GBI Research Report Guidance 10
3 Global Diabetes Market: Market Overview 11
3.1 Introduction 11
3.2 Unmet Needs 11
3.2.1 Heart Risks Associated with some of the Oral Anti-diabetic Drugs 11
3.2.2 Carcinogenic Effects Associated With Insulin Analogs 12
3.2.3 Poor Patient Compliance 12
3.3 Revenue 12
3.4 Annual Cost of Therapy 14
3.5 Treatment Usage Patterns 15
3.5.1 Diseased Population 17
3.5.2 Treatment Seeking Population 18
3.5.3 Diagnosed Population 19
3.5.4 Prescription Population 20
3.6 Drivers and Restraints of Diabetes Market 21
3.6.1 Drivers of Diabetes Market 21
3.6.2 Restraints of Diabetes Market 21
4 Global Diabetes Market: Geographical Landscape 23
4.1 The US 25
4.1.1 Revenue 25
4.1.2 Annual Cost of Therapy 27
4.1.3 Treatment Usage Patterns 28
4.2 Top Five EU Countries 33
4.2.1 Revenue 33
4.2.2 Annual Cost of Therapy 35
4.2.3 Treatment Usage Patterns 36
4.3 Japan 41
4.3.1 Revenue 41
4.3.2 Annual Cost Therapy 42
4.3.3 Treatment Usage Patterns 43
5 Global Diabetes Market: Therapeutic Landscape 48
5.1 Type 1 Diabetes Market 48
5.1.1 Introduction 48
5.1.2 Symptoms 48
5.1.3 Treatment 48
5.1.4 Unmet need 50
5.1.5 Revenue 51
5.1.6 Annual Cost of therapy 52
5.1.7 Treatment Usage Patterns 54
5.1.8 Drivers and Restraints for the Type 1 Diabetes Market 60
5.2 Type 2 diabetes Therapeutics Market 61
5.2.1 Introduction 61
5.2.2 Symptoms 61
5.2.3 Treatment 62
5.2.4 Unmet need 62
5.2.5 Revenue 63
5.2.6 Annual Cost of therapy 64
5.2.7 Treatment Usage Patterns 66
5.2.8 Drivers and Restraints for the Type 2 Diabetes Market 72
5.3 Revenues by Class of Drugs of Type 2 Diabetes 74
6 Global Diabetes Market: Pipeline Analysis 77
6.1 Introduction 77
6.1.1 Research and Development Pipeline - Type 1 Diabetes 79
6.1.2 Research and Development Pipeline - Type 2 Diabetes 83
6.2 Innovations in Diabetes Treatment 94
6.2.1 Insulin in Pills (Oral Delivery) 94
6.2.2 Promising Treatments for Diabetic Retinopathy 94
6.2.3 Biomarkers in Diabetes 94
6.2.4 Combination Drugs are an Important Part of the Diabetes Therapeutics Pipeline 94
6.3 Drug Delivery in Diabetes 95
6.3.1 Factors Determining Preference for Drug Delivery 95
6.3.2 Desirable Drug Delivery Methods for Diabetes are Currently Unavailable 95
6.3.3 Innovation in Drug Delivery Systems 96
6.4 Profiles of Promising Drugs in the Diabetes Market 97
6.4.1 rhGAD65 (Diamyd) 97
6.4.2 DiaPep277 97
6.4.3 Otelixizumab 98
6.4.4 Oral-lyn 99
6.4.5 BMS-512148 (dapagliflozin) 100
6.4.6 Victoza (liraglutide) 101
6.4.7 D-Tagatose 103
6.4.8 JNJ-28431754 (canagliflozin) 103
6.4.9 MB07803 104
7 Global Diabetes Market: Competitive Landscape 106
7.1 Diabetes Market Overview 106
7.1.1 Human Insulin Products and Oral Anti-diabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth 106
7.2 Market Share Analysis: Diabetes 107
7.3 Competitive Profiling 108
7.3.1 Novo Nordisk 109
7.3.2 Sanofi-Aventis 116
7.3.3 Takeda 121
7.3.4 Eli Lilly 124
7.3.5 GlaxoSmithKline (GSK) 130
7.3.6 Merck and Co Inc 134
7.3.7 Amylin Pharmaceuticals 137
8 Global Diabetes Market: MandA Landscape 141
8.1 Overview 141
8.1.1 MandA by Geography 142
8.1.2 MandA by Value ($) 143
8.2 RandD Licensing Agreements 143
8.2.1 Deals by Geography 145
8.2.2 Deals by Value ($) 146
9 Global Diabetes Market: Appendix 147
9.1 Market Definitions 147
9.2 Abbreviations 147
9.3 Research Methodology 149
9.3.1 Coverage 149
9.3.2 Secondary Research 149
9.3.3 Primary Research 149
9.3.4 Forecasts 150
9.3.5 Expert Panel Validation 152
9.4 Contact Us 153
9.5 Disclaimer 153
9.6 Sources 1531.1 List of Tables
Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 13
Table 2: Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 13
Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 15
Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 15
Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 16
Table 6: Diabetes Therapeutics Market, Global, Treatment Usage Patterns(millions), 2009-2016 16
Table 7: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2009 23
Table 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2009-2016 24
Table 9: Diabetes Market, The US, Revenues ($bn), 2001-2009 26
Table 10: Diabetes Therapeutics Market, The US, Revenues ($bn), 2009-2016 26
Table 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2009 27
Table 12: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2009-2016 27
Table 13: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2009 28
Table 14: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009-2016 29
Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2001-2009 34
Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenues ($bn), 2009-2016 34
Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2009 35
Table 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2009-2016 35
Table 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2001-2009 36
Table 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2009-2016 37
Table 21: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2001-2009 41
Table 22: Diabetes Therapeutics Market, Japan, Revenue ($bn), 2009-2016 41
Table 23: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009 42
Table 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2016 42
Table 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-2009 43
Table 26: Diabetes Market, Japan, Treatment Usage Patterns(millions), 2009-2016 44
Table 27: Type 1 Diabetes Therapeutics Market, Types of Insulin Regimen 49
Table 28: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 51
Table 29: Type 1 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 51
Table 30: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 53
Table 31: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 53
Table 32: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 55
Table 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 55
Table 34: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2001-2009 64
Table 35: Type 2 Diabetes Therapeutics Market, Global, Revenue ($bn), 2009-2016 64
Table 36: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009 65
Table 37: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016 65
Table 38: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 67
Table 39: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 67
Table 40: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009 75
Table 41: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016 76
Table 42: Type 1 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Phase III, 2010 80
Table 43: Type 1 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Phase II, 2010 81
Table 44: Type 1 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Phase I, 2010 82
Table 45: Type 1 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Preclinical, 2010 82
Table 46: Type 2 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Phase III, 2010 84
Table 47: Type 2 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Phase II, 2010 86
Table 48: Diabetes Market, Global, RandD Pipeline by Phase in Type 2 Diabetes Market, Phase I, 2010 89
Table 49: Type 2 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase, Preclinical, 2010 92
Table 50: Diabetes Therapeutics Markets, Factors Determining Preference of Drug Delivery in Diabetes, 2010 95
Table 51: Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2010 95
Table 52: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2010 114
Table 53: Diabetes Therapeutics Market, Sanofi-Aventis, Pipeline Products, 2010 120
Table 54: Diabetes Market, Takeda, Pipeline Products, 2010 123
Table 55: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2010 128
Table 56: Diabetes Therapeutics Market, GSK, Pipeline Products, 2010 133
Table 57: Diabetes Therapeutics Market, Merck, Pipeline Products, 2010 136
Table 58: Diabetes Therapeutics Market, Amylin, Pipeline Products, 2010 1391.2

List of Figures

Figure 1: Diabetes Therapeutics Market, Global, Revenue($m), 2001-2016 13
Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 14
Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2001-2016 15
Figure 4: Diabetes Therapeutics Market, Global, Diseased Population (‘000), 2001-2016 17
Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016 18
Figure 6: Diabetes Therapeutics Market, Global, Diagnosis Population (‘000), 2001-2016 19
Figure 7: Diabetes Therapeutics Market, Global, Prescription Population (‘000), 2001-2016 20
Figure 8: Diabetes Market, Global, Revenue Analysis by Geography ($bn), 2001-2016 23
Figure 9: Diabetes Therapeutics Market, The US, Revenue ($m), 2001-2016 25
Figure 10: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2001-2016 27
Figure 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (‘000), 2001-2016 28
Figure 12: Diabetes Therapeutics Market, the US, Diseased Population (‘000), 2001-2016 29
Figure 13: Diabetes Therapeutics Market, the US, Treatment Seeking Population (‘000), 2001-2016 30
Figure 14: Diabetes Therapeutics Market, The US, Diagnosis Population (‘000), 2001-2016 31
Figure 15: Diabetes Therapeutics Market, The US, Prescription Population (‘000), 2001-2016 32
Figure 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2001-2016 34
Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2001-2016 35
Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (‘000), 2001-2016 36
Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Diseased Population (‘000), 2001-2016 37
Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population (‘000), 2001-2016 38
Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosis Population (‘000), 2001-2016 39
Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population (‘000), 2001-2016 40
Figure 23: Diabetes Therapeutics Market, Japan, Revenue ($m), 2001-2016 41
Figure 24: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2016 42
Figure 25: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2001-2016 43
Figure 26: Diabetes Therapeutics Market, Japan, Diseased Population (‘000), 2001-2016 44
Figure 27: Diabetes Therapeutics Market, Japan, Treatment Seeking Population (‘000), 2001-2016 45
Figure 28: Diabetes Therapeutics Market, Japan, Diagnosis Population (‘000), 2001-2016 46
Figure 29: Diabetes Therapeutics Market, Japan, Prescription Population (‘000), 2001-2016 47
Figure 30: Type 1 Diabetes Therapeutics Market, Global, Unmet Need, 2010 50
Figure 31: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2001-2016 51
Figure 32: Type 1 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 52
Figure 33: Type 1 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2001-2016 54
Figure 34: Type 1 Diabetes Therapeutics Market, Global, Diseased Population (‘000), 2001-2016 56
Figure 35: Type 1 Diabetes Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016 57
Figure 36: Type 1 Diabetes Therapeutics Market, Global, Diagnosis Population (‘000), 2001-2016 58
Figure 37: Type 1 Diabetes Therapeutics Market, Global, Prescription Population (‘000), 2001-2016 59
Figure 38: Type 1 Diabetes Therapeutics Market, Global, Drivers and Restraints, 2009 61
Figure 39: Type 2 Diabetes Therapeutics Market, Global, Unmet Need, 2010 62
Figure 40: Type 2 Diabetes Therapeutics Market, Global, Revenues ($m), 2001-2016 63
Figure 41: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016 64
Figure 42: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2001-2016 66
Figure 43: Type 2 Diabetes Therapeutics Market, Global, Diseased Population (‘000), 2001-2016 68
Figure 44: Type 2 Diabetes Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016 69
Figure 45: Type 2 Diabetes Therapeutics Market, Global, Diagnosis Population (‘000), 2001-2016 70
Figure 46: Type 2 Diabetes Therapeutics Market, Global, Prescription Population (‘000), 2001-2016 71
Figure 47:Type 2 Diabetes Therapeutics Market , Global, Market Drivers and Barriers, 2009-2016 73
Figure 48: Type 2 Diabetes Therapeutics Market , Global, Market Share by Class of Drugs, 2009-2016 74
Figure 49: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2001-2009 75
Figure 50: Type 2 Diabetes Therapeutics Market, Global, Revenues By Class of Drugs ($bn), 2009-2016 76
Figure 51: Diabetes Therapeutics Market, Global, RandD Pipeline by Indication (%), 2010 77
Figure 52: Diabetes Therapeutics Market, Global, RandD Pipeline by Phase (%), 2010 78
Figure 53: Type 1 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase (%), 2010 79
Figure 54: Type 2 Diabetes Therapeutics Market, Global, RandD Pipeline by Phase (%), 2010 83
Figure 55: Diabetes Therapeutics Market, Global, Share of Top Manufacturers (%), 2010 107
Figure 56: Diabetes Therapeutics Market, Global, Revenue of Top Seven Players ($m), 2007-2009 108
Figure 57: Diabetes Therapeutics Market, Novo Nordisk, Revenue Segments (%), 2009 110
Figure 58: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Product (%), 2009 111
Figure 59: Diabetes Therapeutics Market, Novo Nordisk, SWOT Analysis, 2010 115
Figure 60: Diabetes Therapeutics Market, Sanofi-Aventis, Revenue Segment (%), 2009 116
Figure 61: Diabetes Therapeutics Market, Sanofi-Aventis, Diabetes Revenue by Product (%), 2009 117
Figure 62: Diabetes Therapeutics Market, Sanofi-Aventis, SWOT Analysis, 2010 120
Figure 63: Diabetes Therapeutics Market, Takeda, Revenue Segments (%), 2009 121
Figure 64: Diabetes Therapeutics Market, SWOT Analysis, Takeda, 2010 123
Figure 65: Diabetes Therapeutics Market, Eli Lilly, Revenue Segments (%), 2009 124
Figure 66: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2009 125
Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly, 2010 129
Figure 68: Diabetes Therapeutics Market , GSK, Revenue Segments (%), 2009 130
Figure 69: Therapeutics Market, GSK, Diabetes Revenue by Product (%), 2009 131
Figure 70: Diabetes Therapeutics Market, GSK, SWOT Analysis, 2010 133
Figure 71: Diabetes Therapeutics Market, Merck, Diabetes Revenue as Percentage of Total Revenue (%), 2009 134
Figure 72: Diabetes Therapeutics Market, Merck, SWOT Analysis, 2010 136
Figure 73: Diabetes Therapeutics Market, Amylin, Diabetes Revenue as Percentage of Total Revenue (%), 2009 137
Figure 74: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2009 138
Figure 75: Diabetes Therapeutics Market, Amylin, SWOT Analysis, 2010 140
Figure 76: Diabetes Therapeutics Market, Global, Major MandAs By Geography (%), n=48, 2009-2010 142
Figure 77: Diabetes Therapeutics Market, Global, Major MandAs By Value ($), n=48, 2009-2010 143
Figure 78: Diabetes Therapeutics Market, Global, Major Licensing Agreements By Geography ($), n=76, 2009-2010 145
Figure 79: Diabetes Therapeutics Market, Global, Major Licensing Agreement By Value ($), n=76, 2009-2010 146
Figure 80: GBI Research Market Forecasting Model 152

Companies mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.